Unamity 4mg Tablet 14’S (Baricitinib) Lilly

Unamity (Baricitinib) 4mg Tablet, manufactured by Lilly, is an oral medication used to treat autoimmune diseases such as rheumatoid arthritis and alopecia areata. It is a selective Janus kinase (JAK) inhibitor that helps manage inflammation and immune responses, providing relief from pain and swelling for people with autoimmune disorders.

How It Works

Baricitinib, the active ingredient in Unamity, belongs to a class of medications known as Janus Kinase (JAK) inhibitors. These enzymes play a key role in transmitting signals from cytokine or growth factor receptors to the immune system, triggering inflammation and immune responses. Baricitinib works by inhibiting JAK1 and JAK2 enzymes, effectively reducing the immune system’s overactivity in conditions like rheumatoid arthritis.

1. Targeting JAK Pathways: By blocking JAK1 and JAK2 signaling, Unamity interferes with the communication between cells that produce cytokines (proteins that promote inflammation).
2. Reducing Immune Response: This inhibition of the JAK pathway reduces the immune system’s excessive response, which in autoimmune diseases can mistakenly target the body’s own tissues.
3. Controlling Inflammation: The primary effect is a significant reduction in inflammation, which leads to less joint pain, reduced swelling, and overall better management of autoimmune symptoms.

Side Effects

Though effective, Unamity (Baricitinib) may cause several side effects, some of which can be serious. Patients are encouraged to monitor for these and report any adverse effects to their healthcare provider. Common Side Effects:

• Upper respiratory tract infections (e.g., cold, sore throat)
• Nausea
• Headache
• Elevated liver enzymes
• High cholesterol levels

Serious Side Effects:

• Blood clots (deep vein thrombosis or pulmonary embolism)
• Increased risk of infections (including tuberculosis and herpes zoster)
• Low blood cell counts (anemia, neutropenia)
• Gastrointestinal perforation
• Elevated liver enzyme levels
• Potential for malignancies with long-term use (risk of certain cancers)

Indications

Unamity is primarily indicated for:

1. Rheumatoid Arthritis (RA): For adult patients with moderate to severe rheumatoid arthritis who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs).
2. Alopecia Areata: For patients with severe alopecia areata, an autoimmune disorder where the immune system attacks hair follicles, leading to hair loss.
3. COVID-19: Baricitinib has received emergency use authorization for treating hospitalized patients with COVID-19 who require oxygen therapy or ventilation, to reduce severe inflammation.

Contraindications

Unamity should not be used in certain situations where it may cause harm:

• Hypersensitivity: Individuals with known hypersensitivity or allergy to baricitinib or any of the excipients in the formulation.
• Active or severe infections: Patients with active infections (e.g., tuberculosis, severe bacterial infections, or viral infections like hepatitis) should avoid taking Unamity until the infection is fully treated.
• Liver Disease: Those with severe liver impairment should not use Unamity as it can worsen liver function.
• Pregnancy and Breastfeeding: It is contraindicated in pregnant or breastfeeding women unless absolutely necessary, due to potential risks to the fetus or infant.
• Chronic Kidney Disease: Patients with severe renal impairment may need dosage adjustments or may be advised against using this medication.

Price in Different Countries

Country	Price (4mg, per pack of 14)	Reference
United States	$1,500 – $2,000	GoodRx
United Kingdom	£1,200 – £1,500	Medicines.org.uk
Australia	AUD 2,300 – AUD 2,600	PBS.gov.au
India	₹140,000 – ₹180,000	1mg

Top 5 Global Brands

1. Olumiant (Eli Lilly): The original branded version of Baricitinib, known for its efficacy in treating autoimmune conditions such as rheumatoid arthritis.
2. Rinvoq (AbbVie): Another JAK inhibitor used for rheumatoid arthritis, providing an alternative to Baricitinib.
3. Xeljanz (Pfizer): A competitor JAK inhibitor that treats autoimmune conditions like rheumatoid arthritis, ulcerative colitis, and psoriatic arthritis.
4. Jakavi (Novartis): While not identical, this JAK inhibitor treats myeloproliferative disorders like myelofibrosis and polycythemia vera.
5. Tavneos (ChemoCentryx): A new immunomodulatory drug for autoimmune conditions, though it targets a different mechanism than JAK inhibitors.